Polyphenolic Polymer Water-Soluble Drug Nanoparticles
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current drug formulations for poorly water-soluble drugs like paclitaxel and bexarotene face challenges due to their poor solubility, leading to toxic side effects and manufacturing issues, such as hypersensitivity reactions and microbial contamination, and existing solutions like Cremophor and albumin-based formulations are not ideal due to toxicity and contamination risks.
Innovation Solution
A Polyphenolic Polymer platform is developed, combining a water-insoluble pharmacologically active agent with a complementary polyphenol and a polymer, which is then processed to form nanoparticles, creating a water-soluble hybrid drug composition that is less toxic and more bioavailable, eliminating the need for solubilizing agents like Cremophor or albumin.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If Cremophor EL is used as a solubilizing vehicle for paclitaxel, then the drug becomes soluble in water, but severe hypersensitivity reactions occur and premedication is required
Solution Approach 1:
The patent uses albumin as an intermediary carrier to solubilize paclitaxel. Instead of using Cremophor EL directly, the drug is bound to albumin which then serves as the solubilizing agent, eliminating the hypersensitivity reactions associated with Cremophor while maintaining solubility
Solution Approach 2:
The invention creates a composite formulation combining paclitaxel with albumin to form albumin-bound paclitaxel. This composite material provides both the solubility benefits of a carrier system and the safety benefits of avoiding toxic solubilizing agents like Cremophor EL
2Reliability
If albumin is used as a carrier to make paclitaxel particles, then the drug becomes more bioavailable, but manufacturing becomes difficult due to contamination and antigenicity risks
Solution Approach 1:
The patent employs a simplified manufacturing approach using commercially available human serum albumin as a disposable carrier. The formulation is designed for single-use vials that are reconstituted at the point of administration, eliminating the need for complex sterilization and purification processes that would be required for reusable protein-based carriers
Solution Approach 2:
The patent uses pre-manufactured, commercially available albumin as the carrier protein, which has already undergone purification and quality control. This preliminary preparation eliminates the need for complex in-house protein purification and characterization processes, significantly simplifying manufacturing while maintaining bioavailability
3Volume of moving object
If paclitaxel is formulated in high concentration, then the dosing volume is reduced, but the formulation requires large dilution volumes and long infusion times
Solution Approach 1:
The patent changes the solubility parameters of paclitaxel by using albumin as a carrier, enabling the formulation of high-concentration stocks that can be easily diluted. The albumin-bound formulation allows for concentration optimization without the constraints of Cremophor-based systems, reducing both dosing volume and infusion time
4Quantity of substance
If Cremophor-based formulation is used, then paclitaxel is soluble, but large dilution volumes are required resulting in large infusion volumes
Solution Approach 1:
The patent uses albumin as an intermediary carrier that binds paclitaxel with high affinity, creating a stable complex that maintains solubility at higher concentrations. This intermediary system eliminates the need for large dilution volumes required by Cremophor-based formulations, as the albumin-bound drug remains soluble at therapeutic concentrations
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The Polyphenolic Polymer platform enhances the solubility and bioavailability of drugs like paclitaxel and bexarotene, reducing toxicity and side effects, while providing a stable and cost-effective formulation that is easier to manufacture and administer.
Implementation Method 1
a Polyphenolic Polymer platform of making a substantially water-solubilized hybrid drug composition comprising: a) providing a first active agent which is at least one substantially water-insoluble pharmacologically active agent
Implementation Method 2
i) subjecting the mixture to evaporative drying, wherein the result of the process is a solubilized hybrid drug composition
Data Source
AI summary
The subject invention relates to compositions of a polyphenolic Polymer and methods useful for the delivery of substantially water-insoluble drugs and agrochemicals, like Artemisinin, Aspirin, and Pyrethrin. The use of specific composition and preparation conditions enables the reproducible production of unusually water-soluble formulation, which can be sterile-filtered. The particulate system produced according to the invention can be converted into a re-dispersible dry powder comprising nanoparticles of drug. The innovation is also based on the fact that complementary polyphenolic partner is also an active drug but may have a different mode action with respect to primary molecule of the hybrid drug. The complementary polyphenol molecule has multiple properties like antioxidant, antimicrobial, anti-inflammatory, anti-allergic, cox-2 inhibitors, etc. This results in a unique delivery system, in which part of the pharmacologically active agent is readily bioavailable. More important the whole process and material used is GRAS approved and environmentally safe.